A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease) Clinical Trial

Official title:

A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared With BGF Delivered by MDI HFA in Participants With Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06075095
• Other study ID #: D5985C00002
• Status: Recruiting
• Phase: Phase 3
• Start date: January 11, 2024
• Est. completion date: September 5, 2025

Study information

• Verified date: June 2024
• Source: AstraZeneca
• Contact: AstraZeneca Clinical Study Information Center
• Phone: 1-877-240-9479
• Email: information.center[@]astrazeneca.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of:

1. A screening and placebo run-in period of approximately 2 weeks prior to first dosing

2. Three treatment periods of approximately 4 weeks each (one period for each of 3 study interventions)

3. A final safety follow-up visit via telephone contact approximately 1 to 2 weeks after the final dose administration Participants will be provided with rescue SABA (albuterol or salbutamol) to be used as needed throughout the study. Participants will attend in-clinic study visits approximately weekly during the screening/run-in period (Visits 1, 2, and 3), then every 4 weeks (Visits 4, 5, and 6) to receive take-home study treatment, measure their lung function, and assess their health and safety

Description:

This is a phase III, randomised, placebo-controlled, double-blind, multi-centre, 4-week, 3-way crossover pharmacodynamic study to assess the equivalence of BGF MDI HFO compared with BGF MDI HFA in participants with COPD. To demonstrate assay sensitivity, BGF MDI HFA will be compared to placebo MDI HFA for superiority in lung function, both pre- and post-dose.

Eligible participants are between 40 and 80 years of age, inclusive, who have an established clinical history of COPD as defined by the ATS/ERS. Participants are required to have an FEV1/FVC ratio of < 0.70, have a post-bronchodilator FEV1 ≥ 40% and < 80% predicted normal value, have a blood eosinophil count < 300 cells/μL, and be current or former cigarette smokers with a history of at least 10 pack-years. Participants must not have had a COPD exacerbation treated with oral corticosteroids or antibiotics within 4 months prior to initiation of screening, and must not have had a COPD exacerbation that required hospitalisation within 12 months prior to initiation of screening. Eligible participants are those on treatment with LABA, LAMA, LAMA/LABA (open or fixed-dose combination), ICS/LABA (open or fixed-dose combination) inhaled maintenance therapies, or SABA, SAMA, or SAMA/SABA scheduled or as-needed inhaled therapies, or who are naïve to COPD therapy.

This study will be conducted at approximately 95 sites globally. After screening, participants will be randomised 1:1:1:1:1:1 to receive study interventions in one of 6 possible treatment sequences.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 240
• Est. completion date: September 5, 2025
• Est. primary completion date: September 5, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

Age

1. Participants must be 40 to 80 years inclusive at the time of signing the ICF. Type of Participant and Disease Characteristics

2. Participants who have a documented history of physician-diagnosed COPD as defined by the ATS/ERS (Celli et al 2004).

3. Participants who have been receiving LABA, LAMA, LAMA/LABA, or ICS/LABA inhaled maintenance therapies for the management of their COPD for at least 4 weeks prior to Visit 1, OR Participants who have been receiving SABA, SAMA, or SABA/SAMA either scheduled or as needed for at least 4 weeks prior to Visit 1, OR Participants who are COPD treatment-naïve or have not received previously prescribed COPD treatment in the 4 weeks prior to Visit 1.

4. At Visit 1: Participants with a blood eosinophil count < 300 cells/µL.

5. At Visit 1: Participants with a pre-bronchodilator FEV1 of < 80% predicted normal.

6. At Visit 2: Participants with a post-bronchodilator FEV1/FVC ratio of < 0.70 and a postbronchodilator FEV1 of = 40% to < 80% predicted normal.

7. At Visit 3 (TP 1 Day 1): Participants with a pre-dose FEV1 of < 80% predicted normal that is within ± 20% or 200 mL of their Visit 2 pre-bronchodilator FEV1 and an FEV1/FVC ratio of < 0.70.

8. Current or former smokers with a history of at least 10 pack-years of tobacco smoking

1. pack-year = 20 cigarettes smoked per day for one year). 9 Participants who are willing and, in the opinion of the Investigator, able to adjust current COPD therapy, as required by the protocol. Sex and Contraceptive/Barrier Requirements 10 Females must not be of childbearing potential or must use a form of highly effective birth control as defined below:

• Females not of childbearing potential are defined as females who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or postmenopausal. Females will be considered postmenopausal if they have been amenorrhoeic for 52 weeks (12 months) prior to the planned date of randomisation without an alternative medical cause. The following age-specific requirements apply:

• Females < 50 years old would be considered postmenopausal if they have been amenorrhoeic for 52 weeks (12 months) or more following cessation of exogenous hormonal treatment with FSH levels in the postmenopausal range.

• Females = 50 years old would be considered postmenopausal if they have been amenorrhoeic for 52 weeks (12 months) or more following cessation of all exogenous hormonal treatment.

• Female participants of childbearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly.

All FOCBP who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control, as defined below, from enrolment throughout the study and until at least 14 days after the last dose of study intervention. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational [15:32] Lubian, Dominika amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

• All FOCBP must have a negative serum pregnancy test result at Visit 1.

• Females < 50 years of age with amenorrhoea for at least 12 months without an alternative medical cause must have a serum FSH test at Visit 1.

• Highly effective birth control methods are listed below:

• Total sexual abstinence is an acceptable method provided it is the preferred and usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study interventions).

• Combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation:

o Oral

o Intravaginal

o Transdermal

• Progestogen-only hormonal contraception associated with inhibition of ovulation: o Oral

o Injectable

• Implantable

• Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)

• Bilateral tubal occlusion

• Male partner sterilisation/vasectomy with documentation of azoospermia prior to the female participant's entry into the study, and this male is the sole partner for that participant. The documentation on male sterility can come from the site personnel's review of participant's medical records, medical examination and/or semen analysis or medical history interview provided by her or her partner. Informed Consent 11 Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Other Inclusion Criteria 12 Participants with calculated eGFR > 30 mL/min/1.73 m2 using the CKD-EPI formula.

13 Participants who demonstrate acceptable MDI administration and spirometry techniques.

14 Participants who remain compliant with placebo run-in administrations, defined as = 80% of planned doses over the last 7 days prior to Visit 3, based on ePRO diary data.

15 Participants who are willing to remain at the study centre as required per protocol to complete all visit assessments.

Exclusion Criteria:

Medical Conditions

1. Confirmed diagnosis of asthma, in the opinion of the Investigator based on thorough review of medical history and medical records.

2. COPD due to a1-antitrypsin deficiency.

3. A COPD exacerbation treated with systemic corticosteroids or antibiotics within 4 months prior to Visit 1 or during the Screening Period.

4. A COPD exacerbation that required hospitalisation within 12 months prior to Visit 1 or during the Screening Period.

5. A respiratory infection ending within 4 weeks prior to Visit 1 or beginning or ending during the Screening Period, per the Investigator's judgement.

6. Life-threatening COPD (eg, need for mechanical ventilation) at any time prior to Visit 1 or during the Screening Period.

7. A SARS-CoV-2 infection in the 8 weeks prior to Visit 1 or during the Screening Period, or that required hospitalisation at any time prior to Visit 1 or during the Screening Period.

8. Sleep apnoea that, in the opinion of the Investigator, is uncontrolled.

9. Other respiratory disorders including, but not limited to, known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis (high-resolution CT evidence of bronchiectasis that causes repeated acute exacerbations), severe neurological disorders affecting control of the upper airway, sarcoidosis, primary ciliary dyskinesia, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or pulmonary thromboembolic disease.

10. Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the Investigator, or any other relevant cardiovascular disorder as judged by the Investigator.

11. Diagnosis of narrow-angle glaucoma that has not been adequately treated, or a change in vision that may be relevant, in the opinion of the Investigator.

Note: All medications approved for control of intraocular pressures are allowed, including topical ophthalmic nonselective beta-blockers and prostaglandin analogues.

12. Symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that, in the opinion of the Investigator, is clinically significant.

13. Unresectable cancer that has not been in complete remission for at least 5 years prior to Visit 1. Note: Squamous cell and basal cell carcinomas of the skin are allowed.

14. Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, haematological, neurological, endocrine, gastrointestinal, or pulmonary. Immune deficiency disorders (ie, HIV infection) should be excluded even if controlled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the participant at risk through participation, or that could affect the efficacy or safety analysis if the disease/condition is exacerbated during the study.

15. Participants with a known hypersensitivity to beta2-agonists, muscarinic antagonists, or corticosteroids, or any component of the MDI.

16. Known history of drug or alcohol abuse within 12 months of Visit 1 or known abuse at any time during the study.

17. History of QT prolongation associated with another medication that required discontinuation of that medication.

Prior/Concomitant Therapy

18. Unable to abstain from short-acting bronchodilators within 6 hours prior to lung function testing at each study visit.

19. Pulmonary resection or lung volume reduction surgery during the 6 months prior to Visit 1 (ie, lobectomy, bronchoscopic lung volume reduction [endobronchial blockers, airway bypass, endobronchial valves, thermal vapour ablation, biological sealants, and airway implants]).

20. Long-term-oxygen therapy or nocturnal oxygen therapy required for greater than 15 hours per day.

Note: As-needed oxygen use is allowed.

21. Trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Visit 1.

22. Unable to abstain from any protocol-defined prohibited medications during the Screening or Treatment Periods (see Section 6.9).

23. Use of any herbal products by either inhalation or nebuliser within 2 weeks prior to Visit 1 or refusal to stop use for the duration of the study.

Prior/Concurrent Clinical Study Experience

24. Participation in another clinical study with a study intervention administered within 30 days or 5 half-lives, whichever is longer, prior to Visit 1.

Diagnostic Assessments

25. Participants with ECG QTcF interval > 480 milliseconds.

26. Participants with high-degree atrioventricular block II or III, or with sinus node dysfunction with clinically significant pauses who are not treated with pacemaker.

27. Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs, or ECG which, in the opinion of the Investigator, may put the participant at risk because of their participation in the study.

Other Exclusions

28. Planned hospitalisation during the study.

29. Involvement in the planning or conduct of the study (applies to both AstraZeneca staff and staff at the study sites).

30. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members.

31. Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

32. Previous randomisation in the present study.

33. For women only: currently pregnant (confirmed with positive pregnancy test), breastfeeding, or planned pregnancy during the study, or FOCBP not using acceptable contraception measures.

Related Conditions & MeSH terms

• COPD (Chronic Obstructive Pulmonary Disease)
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• BGF MDI HFO 320/14.4/9.6µg
Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)
• BGF MDI HFA 320/14.4/9.6 µg
Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart):
• Placebo MDI HFA
Study interventions will be administered orally via MDI as 2 inhalations BID (every morning and evening, approximately 12 hours apart)

Locations

Country	Name	City	State
Argentina	Research Site	Buenos Aires
Argentina	Research Site	Buenos Aires
Argentina	Research Site	Quilmes
Argentina	Research Site	Rosario
Argentina	Research Site	San Fernando
Bulgaria	Research Site	Dupnitsa
Bulgaria	Research Site	Pernik
Bulgaria	Research Site	Pleven
Bulgaria	Research Site	Ruse
Bulgaria	Research Site	Sofia
Bulgaria	Research Site	Sofia
Bulgaria	Research Site	Veliko Tarnovo
Bulgaria	Research Site	Vratsa
Canada	Research Site	Burlington	Ontario
Canada	Research Site	Guelph	Ontario
Canada	Research Site	Quebec
Canada	Research Site	St Charles Borromee	Quebec
Canada	Research Site	Truro	Nova Scotia
Hungary	Research Site	Balassagyarmat
Hungary	Research Site	Budapest
Hungary	Research Site	Gödöllo
Hungary	Research Site	Hajdúnánás
Hungary	Research Site	Mosonmagyaróvár
Hungary	Research Site	Pécs
Hungary	Research Site	Püspökladány
India	Research Site	Ajmer
India	Research Site	Aligarh
India	Research Site	Coimbatore
India	Research Site	Jaipur
India	Research Site	Kanpur
India	Research Site	Mangalore
India	Research Site	Surat
Korea, Republic of	Research Site	Daegu
Korea, Republic of	Research Site	Jeonju
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Ulsan
Malaysia	Research Site	George Town
Malaysia	Research Site	Ipoh
Malaysia	Research Site	Kuala Lumpur
Malaysia	Research Site	Kuala Terengganu
Mexico	Research Site	Benito Juarez
Mexico	Research Site	Chihuahua
Mexico	Research Site	Cuernavaca
Mexico	Research Site	Cuernavaca
Mexico	Research Site	Merida
Mexico	Research Site	Monterrey
Mexico	Research Site	Zapopan
Philippines	Research Site	Iloilo City
Philippines	Research Site	Las Pinas
Philippines	Research Site	Manila
Philippines	Research Site	Quezon City
Poland	Research Site	Checiny
Poland	Research Site	Jelenia Góra
Poland	Research Site	Lublin
Poland	Research Site	Sosnowiec
Thailand	Research Site	Chiang Mai
Thailand	Research Site	Hat Yai
Thailand	Research Site	Khon Kaen
Thailand	Research Site	Muang
Turkey	Research Site	Ankara
Turkey	Research Site	Dinar
Turkey	Research Site	Istanbul
Turkey	Research Site	Istanbul
Turkey	Research Site	Izmir
Turkey	Research Site	Izmir
Turkey	Research Site	Kayseri
United States	Research Site	Boerne	Texas
United States	Research Site	Bronx	New York
United States	Research Site	Chicago	Illinois
United States	Research Site	Clearwater	Florida
United States	Research Site	Dublin	Ohio
United States	Research Site	El Paso	Texas
United States	Research Site	Gaffney	South Carolina
United States	Research Site	Gainesville	Florida
United States	Research Site	Medford	Oregon
United States	Research Site	Miami	Florida
United States	Research Site	Northridge	California
United States	Research Site	Nottingham	Maryland
United States	Research Site	Orlando	Florida
United States	Research Site	Philadelphia	Pennsylvania
United States	Research Site	Portland	Oregon
United States	Research Site	Raleigh	North Carolina
United States	Research Site	Rincon	Georgia
United States	Research Site	Saint Charles	Missouri
United States	Research Site	Saint Louis	Missouri
United States	Research Site	Sheffield	Alabama
United States	Research Site	Tampa	Florida
Vietnam	Research Site	Da Nang
Vietnam	Research Site	Ha Noi
Vietnam	Research Site	Hai Phong
Vietnam	Research Site	Hanoi
Vietnam	Research Site	Hanoi
Vietnam	Research Site	Ho Chi Minh
Vietnam	Research Site	Ho Chi Minh
Vietnam	Research Site	Hochiminh

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Vietnam,  Argentina,  Bulgaria,  Canada,  Hungary,  India,  Korea, Republic of,  Malaysia,  Mexico,  Philippines,  Poland,  Thailand,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number (and percentage) of participants with adverse Events	To assess the safety and tolerability of BGF MDI HFO compared to BGF MDI HFA in participants with COPD	Over 16 weeks and per treatment group per 4 weeks treatment period
Other	Number (and percentage) of participants with with potentially clinically significant changes in Blood Pressure	To assess the safety and tolerability of BGF MDI HFO compared to BGF MDI HFA in participants with COPD	Over 16 weeks and per treatment group per 4 weeks treatment period
Other	Number (and percentage) of participants with potentially clinically significant changes in pulse rate	To assess the safety and tolerability of BGF MDI HFO compared to BGF MDI HFA in participants with COPD	Over 16 weeks and per treatment group per 4 weeks treatment period
Other	Changes in FEV1 AUC (0-4)	To determine responsiveness to study intervention for TP 1	Change from baseline at TP 1 Day 1
Other	Mean change in FEV1	To determine time to onset of action for each study intervention	Time to onset defined as the first post-dose timepoint where the mean change from baseline in FEV1 exceeds 100 mL on TP 1 Day 1
Other	Changes in FEV1 AUC (0-4)	To assess superiority of BGF MDI HFO relative to placebo MDI HFA on lung function, pre- and post-dose, in participants with COPD	Change from baseline at Day 29
Other	Change in morning pre-dose trough FEV1	To assess superiority of BGF MDI HFO relative to placebo MDI HFA on lung function, pre- and post-dose, in participants with COPD	Change from baseline at Day 29
Primary	Changes in FEV1 AUC (0-4)	To assess the equivalence of BGF MDI HFO relative to BGF MDI HFA on lung function in participants with COPD	Change from baseline at Day 29
Primary	Change in morning pre-dose trough FEV1	To assess the equivalence of BGF MDI HFO relative to BGF MDI HFA on lung function in participants with COPD	Change from baseline at Day 29
Primary	Changes in FEV1 AUC (0-4)	To demonstrate assay sensitivity via superiority of BGF MDI HFA relative to placebo MDI HFA on lung function in participants with COPD	Change from baseline at Day 29
Primary	Change in morning pre-dose trough FEV1	To demonstrate assay sensitivity via superiority of BGF MDI HFA relative to placebo MDI HFA on lung function in participants with COPD	Change from baseline at Day 29